Addiction to MEK inhibitor has been demonstrated in trametinib-resistant lung adenocarcinoma cell lines through genetic alternations in the MAPK signaling pathway leads to hyperactivation of ERK2 and apoptosis after trametinib withdrawal [31]. This evidence concerns the gene MAPK1 and lung adenocarcinoma.